AIT-082 is a purine derivative with neuroprotective and neurotrophic activity that is desirable in a candidate therapy for Amyotrophic Lateral Sclerosis. Consequently, we investigated the effect of AIT-082 in a transgenic mouse model of ALS. AIT-082 (0, 1,3, 10,30, 60, 100 mg/kg) was given to TgN(SOD1-G93A)IGur transgenic mice from age 30 days until death. The age at onset of clinical signs of disease and the age at death were recorded for each animal. Disease progression was measured by the weekly average distance run in a running wheel. Analysis was made by the Kaplan Meier method with log rank statistics, log rank for trend and Cox regression. Neuropathological study of the brain, spinal cord, muscles and other organs was undertaken at death. In a second experiment we studied the effect of AIT-082 (30 mg/kg) at the onset of disease and during survival of transgenic G93A SODI mice, beginning dosing at different ages (20, 30, 40, 60, 80 days). Disease onset was mildly earlier (i.e. worse) at 1 and 10 mglkg AIT-082 and mildly delayed at 30 mg/kg. This improvement did not reach the usual statistical significance. There was no difference in the age at death for any treatment dose. There was no difference in the neuropathology of treated and untreated G93A mice. However, there was an early improvement in the running wheel function at all tested doses. Using Cox regression, after adjustment for sex, the mice in the running wheels had slightly delayed onset of disease without change in survival and, after adjustment for exercise, the female mice had slightly improved survival. Consequently, AIT-082 would not be an attractive candidate for ALS clinical trials as monotherapy and justification for its use in combination therapy would require additional laboratory support. There was dissociation between the endpoints of disease progression (as judged by running wheel performance) and disease onset and survival. AIT-082 improved early running wheel performance yet led to accelerated late decline and had no impact on survival. It is possible that the drug facilitates early sprouting that leads to accelerated late decline.
Amyotrophic Lateral Sclerosis (ALS) is a fatal neuromuscular disease, mostly without a known cause. In a small minority of patients the disease is inherited (familial ALS), and in a fifth of these families a mutation in the copper/zinc superoxide dismutase (SOD-I) gene can be identified (1-2). The mechanisms whereby such mutations lead to disease remain elusive. However, sporadic and familial ALS are clinically indistinguishable and it is hoped that lessons learned in familial ALS will be broadly relevant. Regardless of proximate cause, oxidative stress, excitotoxicity and apoptosis have all been implicated in the terminal death of motor neurons (3) (4) (5) (6) (7) (8) (9) .
Neurotrophic factors may positively affect each of these processes and are therefore of therapeutic interest in ALS (10-11). Neurotrophic factors could correct a growth factor deficiency in ALS (12) or act pharmacologically (in the absence of deficiency). Growth factor deficiency could result from the impaired retrograde transport of factors trophic to motor neurons (13) , secondary to the proximal filamentous axonopathy that characterizes ALS. Alternatively, inherited deficiency of specific growth factors could lead to motor neuron disease ( I0) or potentiate the course of familial ALS (14) . Pharmacological administration of exogenous neurotrophic factors has reduced excitotoxic, oxidative and apoptotic damage in many conditions and has improved the outcomes in ALS mouse models (10, [14] [15] [16] [17] [18] [19] .
However, to date, experience with these agents has been disappointing. CNTF (20) , BDNF (21) , IGF (22) , TSH (23) and GH (24) have all failed in human trials, perhaps because the level of growth factor in the central nervous system is too low after systemic administration, perhaps because the appropriate growth factor has yet to be tried, or perhaps because multiple growth factors need to be given (10).
A IT-0 82 (4-[[3-( I ,6-dihydro-6-oxo-9-purin-9yl)-I-oxo-propyl]amino]benzoic acid), (leteprinim potassium, Neotrophin) is a hypoxanthine derivative with multiple actions. AIT-082 raises levels of many endogenous growth factors. In cultured astrocytes, AIT-082 raises mRNA levels of NGF, NT-3, bFGF (25) and transforming growth factor-beta (26) . It also raises the extracellular levels of adenosine and inosine in astrocyte cultures (26) , and these purines are thought to have direct and indirect trophic and neuroprotective functions (25) . AIT-082 causes axonal sprouting in cultured PC 12 cells (27) and from injured neurons (28) . It protects hippocampal and neocortical neurons from excitotoxic damage in vitro and in vivo (26, 28) , and spinal neurons from crush injury (27, 29) . The drug readily crosses into the central nervous system (30) , and is well tolerated. The antiexcitotoxic and anti-oxidative properties, the direct and indirect potentiation of multiple growth factors, the tolerability and ready access to the central nervous system, together circumvent putative difficulties with other neurotrophic factors, and make AIT-082 an attractive agent to investigate in ALS.
Transgenic SOD-I mice that over-express human mutant SOD-I have been widely used to model ALS and screen potential therapies (31) (32) . Therefore, we assessed the effect of AIT-082 in a G93A SOD-I mouse model over a range of doses. For each dose, we examined the effect of AIT-082 on disease onset and death. We examined the effect on disease progression as judged by distance run in running wheels, using the approach reported by Gurney (33) . Finally, we examined the effect ofAIT-082 on brain and spinal cord histopathology.
We undertook a second experiment to elucidate the mode of action of AIT-082. If AIT-082 were acting as a neuroprotectant, we reasoned that its benefit should decrease the later in life the drug is started. Therefore, we measured the effect of AIT-082 on disease onset and survival, starting the drug at different ages.
MATERIALS AND METHODS
All experiments were performed in compliance with the Animals for Research Act of Ontario and with the guidelines of the Canadian Council on Animal Care, and were approved by the Animal Research Ethics Board of McMaster University.
G93A SOD-I transgenic mice [B6SJL-TgN(SOD-IG93A) IGur] were obtained as breeding pairs from Jackson laboratories. Pregnant dams were maintained in a barrier facility. Pups were genotyped by tailsnip at 30 days of age, using PCR amplification of markers specific to the human SOD-I transgene, following the protocol on the Jackson Laboratories web site (www.Jax.org). Following weaning, animals were individually housed in a 12 hour light/dark cycle. The animals were examined daily. The age at onset of first signs was recorded (abnormal splaying of the hind limbs on suspension by the tails), as described by Gurney (33) . Certain animals (below) were housed in cages with running wheels from day 50 onwards. We measured disease progression by recording the average number of turns per half-hour per animal per 12 hour dark cycle, from day 75 to death, also as described by Gurney (33) .
As animals became weaker, food and water were provided at cage floor level. Animals were euthanized and death was recorded when they could no longer satisfactorily access either food or water or were unable to right themselves within 30 sec after being placed on their sides, consistent with previous reports and as approved by the McMaster University animal research ethics board. In preparation for histology, the animals were given a lethal injection of pentobarbital anesthetic and then perfused with 10% formaldehyde solution by intracardiac puncture for 2 minutes. The organs and the brain and spinal cord were removed and placed in 10% formalin for 2 weeks, prior to sectioning, mounting and staining (all as below).
AIT-082 was obtained from Neotherapeutics (Irvine, CA) [now Spectrum Pharmaceuticals]. In the doseranging experiment, transgenic mice of either sex were treated with 0, 3.3, 10, 33, 100, 200, 333 mg/I AIT-082 in the drinking water from age 30 days onwards. [This route of exposure and these doses were recommended by Neotherapeutics based on preclinical studies, and bracket doses found effective in other animal models (Dr Eve Taylor, Neotherapeutics, personal communication)]. Daily intake of fluid was not affected by treatment and averaged 6-7 ml/d per mouse, and calculated AIT-082 intake per treatment group was 0, 1,3, 10,30,60, 100 mg! kg/d AIT-082 respectively. A minimum of 12 animals per treatment group were targeted, as suggested by Gurney for this model (33) . Litter mates were distributed uniformly between groups, which resulted in slight variation in group numbers. To contain cost, we housed groups 0, 3, 30, 100 mg/kg individually in the running wheel cages (n = 12 per group), and groups I, 10, 60 mg/kg individually in standard cages (n= 13, II, 17 respectively). Disease onset, distance run (where applicable) and death were recorded. In the time-response experiment, we treated G93A SOD-I transgenic mice with 100 mg/l (30 mg/kg) AIT-082 in the drinking water, beginning at ages 20, 30, 40, 60, 80 days, or with 0 mg/kg (control), (n=12 per group).
Age at onset of signs and age at death were tabulated by the method of Kaplan and Meier, and treatment groups were compared to control using a log-rank test of significance and log-rank test for significance of trend. (This is equivalent to exploring a linear dose-response relationship. We did not explore quadratic or other models of dose-response.) We also calculated the time from disease onset of signs to death, as an additional outcome measure. Outcome measures were stratified by sex and by exercise (wheel in cage or not), and the analysis was further refined using Cox regression, with treatment group, sex, and exercise (wheel in cage or not) as covariates. For those groups in running wheels, the number of wheel-turns per half hour was averaged over a week, and the weekly average for each treated group was compared to control using a t test (planned comparison).
Neuropathology was undertaken on three groups (each n=12) of animals: G93A SOD-I mice treated with AIT-082 30 mg/kg from day 30 until death, G93A SOD-I mice receiving no treatment until death (positive controls), and litter mates testing negative for the G93A transgene (negative controls), sacrificed at the same age as the positive controls. All neuropathology sections were scored by a single veterinary neuropathologist (JK), blinded to treatment group. Eight sections were taken from each animal (brain with thalamus, brain with midbrain, brain with cerebellum and medulla, cervical cord, upper thoracic cord, lower thoracic cord, lumbar cord, sacral cord). In addition, the diaphragm and paraspinal and gastrocnemius muscles were examined for each animal. Each section was examined and scored for (where appropriate): neuronal necrosis, neuronal vacuolation, astrogliosis, axonal degeneration, muscle atrophy. A simple 0-4 grading scale was used for each section (no, mild, moderate, marked, severe change, respectively). For descriptive purposes, the median and standard deviation of the 12 animals within each treatment group was recorded for each anatomical level and for each neuropathological abnormality. The planned comparison for the categorical data was active treatment against positive control (Chi square), with Bonferroni correction for multiple sampling.
Since there was no difference in either age at onset or death between the control (untreated) group of the doseranging experiment (n=12) and the control (untreated) group of the time-response experiment (n=12), these were 
RESULTS

Experiment 1: Dose-response
The Kaplan Meier estimates for the average age at onset of disease signs, at death and the average survival after onset of signs, are shown for each experimental group in Table I , along with the standard error of the mean for each. Compared to control, there was a significant difference among groups tested with respect to disease onset (log rank p=0.002). However, the log-rank statistic for trend (which would measure a dose-response effect) was negative (p=0.21, Table I ). Since the variation was mostly due to earl ier disease onset in 2 treated groups, I mg/kg and 10 mg/kg, both housed in cages without running wheels, it is likely that the difference reflects a beneficial effect of exercise on disease onset, as discussed below, rather than a detrimental treatment effect at selected doses. Treatment at 30 mg/kg modestly prolonged disease onset. However, even without correction for multiple sampling, statistical comparison of 30 mg/kg vs control does not reach customary statistical significance (p=0.07). With respect to survival, no treatment group was superior to control (p=0.84, log-rank).
The weekly average of distance run per half-hour from day 75 was tabulated for three doses of AIT-082 (3, 30, 100 mg/kg) and control. The results are surprising. In spite of negative or at best very modest effects on onset and no effect on survival, there was a significant effect on distance run. All doses were better than control early in the experiment (weeks 12, 13, 14) . Of the doses, 30 mg/kg was optimal ( Fig I) . This improvement was not maintained and nearer death, the treated animals showed accelerated decline, such that by time of death all curves were the same.
All G93A animals showed severe neuropathological abnormalities at death entirely consistent with previous reports (34) , and there were no differences between untreated and treated animals. No wildtype animals showed neuropathological abnormalities, confirming the genotyping. There were no drug-related changes in other organs examined [lung, heart, liver, spleen, kidney, adrenal, small intestine, colon, cecum, (urinary) bladder, seminal vesicles (males), coagulating gland (males), vas deferens (males), testis (males), epididymis (males), uterus (females) or cervix (females)] (data not shown).
The age at onset of signs, age at death and time from onset of signs to death, was stratified for sex and exercise (wheel in cage or not) (Table II) . On balance, females did modestly better than males for both disease onset and survival, as did animals caged with running wheels. The analysis was refined using Cox regression adjusting for significant covariates (i.e. sex and exercise, but not the treatment group). The estimated Cox regression curve for the effect of exercise on the onset of signs, after adjustment for sex, is shown in Fig 2. The difference is significant (p = 0.02, Chi square). The estimated Cox curve for the effect of sex on survival, after adjustment for exercise, is shown in Fig 3. The difference is also significant (p = 0.02 Chi square).
We concluded from the dose response experiment that there may have been a modest effect ofAIT-082 at 30 mg/kg on disease onset, no effect on survival, yet significant early improvement in the distance run. However, this is more consistent with a drug-induced symptomatic improvement than neuroprotectant action. If the drug were acting as a neuroprotectant, early treatment should be more efficacious than late treatment, which led us to examine the effect of 30 mg/kg AIT-082 on survival for different treatment (Table III) . We conclude that the results are not supportive of a neuroprotective action of AlT-082, but would be consistent with a symptomatic effect.
DISCUSSION
AIT-082 has many features that should be highly desirable in a treatment for ALS. It directly and indirectly potentiates the actions of multiple growth factors and exhibits anti-excitotoxic and anti-oxidative properties in a variety of models. It is well tolerated and demonstrates ready access to the central nervous system. In spite of these putative benefits, the drug has proven largely ineffective in this transgenic ALS model. At 30 mglkg AIT-082, there may be a modest beneficial effect on disease onset, with no effect on survival, and there is no beneficial effect on disease onset or survival at other doses.
If real, the modest delay in disease onset at 30 mg/kg AIT-082 without survival advantage is consistent with some previous reports of other agents in the SOD-I mouse. It has been suggested, without proof, that there are different mechanisms underlying disease onset and disease progression, and that neuroprotective agents (e.g. vitamin E) may beneficially affect onset but not progression (33) . We can provide only modest support for this observation, and in the case of AIT-082 at least, our experiments do not support the hypothesis that the drug delays disease onset through a neuroprotectant action.
Thus, AIT-082 joins other growth factors and trophic agents as compounds with an attractive rationale yet has no effect in ALS. This failure, in large part, reflects our incomplete understanding of the fundamental pathobiology of the disease. In addition, however, the present experiments could suggest one potential explanation for this futility, and it relates to the running wheel data. Compared to controls, at all three experimental doses tested in the running wheels (3, 30 , 100 mg/kg), there is a relative increase in the distance run, from the time we tabulated data at age 75 days until about I month later, after which there was a steeper decline, such that there was no difference near death. The early increase and later decline is statistically significant.
Although the early improvement in the distance run could have several explanations, the most plausible perhaps, for an agent that is known to promote axonal sprouting, being an early facilitation in compensatory collateral sprouting and relative preservation of strength. However, herein lies a conundrum: survival is not increased and death in our animals almost certainly reflects progressive weakness (by virtue of the way we defined death in the animals). Therefore, any initial improvement must necessarily be coupled with accelerated weakness later in the disease. This could be explained if facilitated axonal sprouting enhances compensatory innervation by surviving motor neurons (hence improving early function), yet the enlarged motor unit size thus produced puts increased metabolic stress on surviving motor neurons and ultimately increases their rate of death (hence accelerating late disease progression). This hypothesis has some mechanistic relevance and would warrant further study. Age at death (days) Fig. 3 . Effect ofsex on survival adjustedfor exercise.
Of some interest, the neurotrophic agent SR57746A (Xaliproden) produced a significant slowing in pulmonary function decline and measures of appendicular weakness in a recent human trial, without significant effect on survival (35) . SR57746A is a neuroprotective and neurotrophic compound that results in increases in mRNA for NGF and BDNF (36) (37) , and in this way is similar in action to AIT-082.
There were no differences in histopathology between treated and untreated SOD I mice at endpoint, and we conclude that AIT-082 did not change the nature (pattern) of the neuropathological deficit. However, using this trial design (wherein the animals were examined at death), small differences in the temporal evolution of the neuropathology might have been missed, had we undertaken serial pathology at defined ages. Given the generally negative effect of the drug, we did not feel further study to prove this point was warranted, nor did we undertake detailed quantimetric analysis.
Because of financial and space constraints, we were unable to provide individual running wheel cages for all the groups of animals. This did allow us to examine the effect of voluntary exercise on disease progression in this model and the interaction of exercise with AIT-082 treatment and with sex. Using the Kaplan Meier approach, with sex and exercise as strata, there was a minor but significant beneficial effect offemale sex and exercise on disease onset and death. With Cox regression, the deleterious effect of AIT-082 treatment at I and 10 mg/kg disappears when exercise is entered as a co-factor (since I, 10, and 60 mg/kg AIT-082 were the three groups housed in normal cages). The protective effect offemale sex is consistent with previous reports (38) , although the mechanism for this remains unclear. Of some interest, when we examine the survival after onset of signs, the exercising animals actually did worse, especially females, and the chief action of exercise may be to delay clinical onset with less effect on survival.
We conclude that AIT-082 would not be an attractive candidate for ALS clinical trials as monotherapy, and justification for its use in combination therapy would require additional laboratory support. It may however, improve function, at least initially. We speculate, without proof at this point, that mal-adaptive sprouting may explain why this increase in function does not translate into increased survival. In spite ofthe attractive rationale, neurotrophic factor supplementation, direct (CNTF, BDNF, IGF) or indirect (SR57746A), has generally proved disappointing in ALS. Recent reports of intramuscular injection of AAV-associated GDNF in mice appear somewhat more promising (39) (40) , and it may be that a therapeutic niche for these agents in ALS will await a more nuanced understanding of their biology.
